Burden of Bowel Urgency in Patients With Ulcerative Colitis and Crohn's Disease: A Real-World Global Study
- PMID: 39281848
- PMCID: PMC11401995
- DOI: 10.1093/crocol/otae047
Burden of Bowel Urgency in Patients With Ulcerative Colitis and Crohn's Disease: A Real-World Global Study
Abstract
Background: Bowel urgency is a highly disruptive and bothersome symptom experienced by patients with inflammatory bowel diseases (IBD), (ulcerative colitis [UC], and Crohn's disease [CD]). However, the burden of bowel urgency among patients with varying experiences in targeted treatment has not been consistently assessed. This real-world study explored the clinical and health-related quality of life burden of bowel urgency among patients with IBD with differing treatment experiences.
Methods: This cross-sectional survey included gastroenterologists and their patients with IBD across France, Germany, Italy, Spain, the United Kingdom, and the United States treated for over 3 months. Physicians provided patient demographics, clinical characteristics, and treatment history. Patients reported their health-related quality of life and work productivity. Patients with UC and CD were analyzed separately and stratified into 3 groups: Targeted therapy naïve, those receiving their first-line targeted therapy, and targeted therapy experienced.
Results: This study found that 17%-26% of UC and 13%-17% of CD patients experienced persistent bowel urgency, irrespective of receiving conventional or targeted therapy. Moreover, patients with bowel urgency experienced an increased clinical and health-related quality of life burden compared to patients without bowel urgency, which physicians most commonly regarded as one of the most difficult symptoms to treat, with the burden remaining substantial irrespective of their treatment experience.
Conclusions: Despite several current treatment options, new therapeutic strategies are necessary to provide relief from bowel urgency, one of the most challenging symptoms for people living with IBD.
Keywords: Crohn’s disease; bowel urgency; quality of life; ulcerative colitis.
© The Author(s) 2024. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.
Conflict of interest statement
I.R., P.S., M.N.P., S.H., G.G., and T.H. are employees of Eli Lilly and Company and may hold stock or stock options; H.K., S.B., and N.H. are employees of Adelphi Real World. R.A. has received grants from AbbVie, Biogen, InDex Pharmaceuticals, Takeda, and Tillotts Pharma; speaker fees from AbbVie, Amgen, Arena, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion Healthcare, Dr. Falk Pharma, Ferring, Fresenius Kabi, Galapagos, InDex Pharmaceuticals, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Pfizer, Roche, Samsung Bioepis, Takeda, and Tillotts Pharma; consulting fees from AbbVie, Arena, Biogen, Boehringer Ingelheim, Galapagos, InDex Pharmaceuticals, Janssen-Cilag, Kliniksa Pharmaceuticals, Lilly, Samsung Bioepis, Stelic Institute, and Takeda.
References
-
- Dawwas GK, Jajeh H, Shan M, Naegeli AN, Hunter T, Lewis JD.. Prevalence and factors associated with fecal urgency among patients with ulcerative colitis and crohn’s disease in the study of a prospective adult research cohort with inflammatory bowel disease. Crohns Colitis 360. 2021;3(3):otab046. doi: 10.1093/crocol/otab046 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources